Q-omics provides the consensus-scored THEG profile across patient tissues and cancer cell-line models. THEG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THEG is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, THEG RNA expression shows 8,448 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where THEG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THEG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THEG survival associations across molecular data types. THEG RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THEG RNA expression–survival associations across cancer types. High THEG expression shows unfavorable associations in KIRC, KICH, STAD, LIHC, MESO and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THEG RNA expression.
This table summarizes THEG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for THEG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THEG shows higher tumor expression in LUAD, KIRC, HNSC, COAD, LUSC and BLCA. The LUAD box plot shows higher THEG RNA expression in tumor versus normal tissue (log2 FC = +1.480, t-test p < 0.001).
This table shows molecular features associated with THEG in patient tissues and cancer cell lines. In patient samples, THEG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, THEG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
